United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases,… byPallavi MadhirajuMay 22, 2024